Market Closed -
Nyse
04:00:01 2024-05-03 pm EDT
5-day change
1st Jan Change
43.99
USD
+0.66%
-1.92%
-14.27%
Bristol Myers Squibb : 2019-2020 Product Sales Summary
May 07, 2020 at 11:54 am EDT
BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
2019
2020
$ Change
% Change
1st Qtr
2nd Qtr
6 Months
3rd Qtr
9 Months
4th Qtr(b)
Year(b)
1st Qtr(c)
2nd Qtr
6 Months
3rd Qtr
9 Months
4th Qtr
Year
Qtr vs. Qtr
YTD vs. YTD
Qtr vs. Qtr
YTD vs. YTD
Prioritized Brands
Revlimid
$
-
$ -
$ -
$ -
$ -
$
1,299
$
1,299
$
2,915
$
2,915
$
2,915
N/A
N/A
Eliquis
1,925
2,042
3,967
1,928
5,895
2,034
7,929
2,641
716
716
37%
37%
Opdivo
1,801
1,823
3,624
1,817
5,441
1,763
7,204
1,766
(35)
(35)
(2)%
(2)%
Orencia
640
778
1,418
767
2,185
792
2,977
714
74
74
12%
12%
Pomalyst/Imnovid
-
-
-
-
-
322
322
713
713
713
N/A
N/A
Sprycel
459
544
1,003
558
1,561
549
2,110
521
62
62
14%
14%
Yervoy
384
367
751
353
1,104
385
1,489
396
12
12
3%
3%
Abraxane
-
-
-
-
-
166
166
300
300
300
N/A
N/A
Empliciti
83
91
174
89
263
94
357
97
14
14
17%
17%
Reblozyl
-
-
-
-
-
-
-
8
8
8
N/A
N/A
Inrebic
-
-
-
-
-
5
5
12
12
12
N/A
N/A
Established Brands
Baraclude
141
147
288
145
433
122
555
122
(19)
(19)
(13)%
(13)%
Vidaza
-
-
-
-
-
58
58
158
158
158
N/A
N/A
Other Brands(a)
487
481
968
350
1,318
356
1,674
418
(69)
(69)
(14)%
(14)%
Total
$
5,920
$
6,273
$
12,193
$
6,007
$
18,200
$
7,945
$
26,145
$
10,781
$
4,861
$
4,861
82%
82%
Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue. Other Brands includes $122 million relating to Celgene products in the three months ended March 31, 2020.
Includes Celgene product revenues from November 20, 2019 through December 31, 2019.
Includes Celgene product revenues for the three months ended March 31, 2020. Attachments
Original document
Permalink
Disclaimer
Bristol-Myers Squibb Company published this content on 07 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2020 15:53:09 UTC
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50
May. 01
MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration
May. 01
MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
May. 01
CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...
Apr. 30
A flurry of corporate results ahead of the Fed's rate decision
Apr. 30
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...
Apr. 30
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb
Apr. 30
CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Apr. 30
RE
J&J, Bristol Myers lose challenges to US drug price negotiation program
Apr. 29
RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60
Apr. 29
MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating
Apr. 29
MT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Apr. 29
CI
S&P 500 Q1 earnings estimated growth improves; stocks up for week
Apr. 26
RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51
Apr. 26
MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating
Apr. 26
MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51
Apr. 26
MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65
Apr. 26
MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy
Apr. 26
MT
Bristol Myers: positive opinion from the CHMP for Opdivo
Apr. 26
CF
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer
Apr. 26
DJ
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40
Apr. 26
MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating
Apr. 26
MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55
Apr. 26
MT
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Apr. 26
CI
Health Care Drops Amid Mixed Earnings -- Health Care Roundup
Apr. 25
DJ
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
More about the company
Last Close Price
43.99
USD
Average target price
53.32
USD
Spread / Average Target
+21.20%
Consensus
1st Jan change
Capi.
-14.27% 89.17B +21.85% 546B -4.77% 359B +16.97% 323B +5.69% 290B +13.68% 234B +3.65% 198B -11.12% 194B +8.08% 167B -3.40% 157B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1